Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs VITAMIN K1
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Vitamin K1 (phytonadione) is a fat-soluble vitamin that serves as a cofactor for the enzyme gamma-glutamyl carboxylase, which catalyzes the carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) on vitamin K-dependent proteins, including clotting factors II, VII, IX, X, and proteins C and S. This carboxylation is essential for their calcium-binding activity and subsequent activation in the coagulation cascade.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Prophylaxis and treatment of vitamin K deficiency bleeding (VKDB) in neonates,Treatment of hypoprothrombinemia due to vitamin K deficiency or anticoagulant (e.g., warfarin) overdose,Reversal of anticoagulant effects of warfarin,Off-label: Treatment of vitamin K deficiency due to malabsorption syndromes, liver disease, or prolonged parenteral nutrition
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
10 mg IV or IM as a single dose for anticoagulant reversal; may repeat every 12-24 hours as needed. For vitamin K deficiency: 2.5-10 mg PO, IM, or IV once daily.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life is approximately 2-3 hours for vitamin K1 oxide, but the pharmacodynamic half-life of clotting factor synthesis is 12-24 hours due to prolonged hepatic effects.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Vitamin K1 is metabolized in the liver via the vitamin K cycle, which involves reduction by vitamin K epoxide reductase (VKOR) and other reductases, followed by reoxidation. The side chain undergoes oxidation and conjugation, with metabolites excreted in bile and urine.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily hepatic metabolism, with metabolites excreted in bile and feces (up to 60-80%). Renal excretion of metabolites accounts for <10% of the dose.
38-45%, primarily bound to albumin.
Highly protein bound (>90%), primarily to lipoproteins and albumin.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Approximately 0.15-0.3 L/kg, reflecting distribution primarily to the liver and limited extravascular binding.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral bioavailability is approximately 50% (range 20-80%) due to limited absorption and first-pass metabolism; intramuscular bioavailability is variable and not recommended; subcutaneous bioavailability is also poor and unreliable.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific dose adjustment recommended for hepatic impairment; use standard dosing with monitoring of INR.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
For anticoagulant reversal: 0.5-2 mg IV or IM as a single dose. For prophylaxis of hemorrhagic disease of newborn: 0.5-1 mg IM within 1 hour of birth.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No specific dose adjustment required; use standard adult dosing with caution due to potential increased sensitivity to anticoagulant reversal.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Intravenous administration of vitamin K1 has been associated with severe reactions, including anaphylaxis, cardiac arrest, and death. Therefore, intravenous use should be reserved for serious or life-threatening situations and should be administered with extreme caution.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Severe hypersensitivity reactions (including anaphylaxis) have occurred, particularly with intravenous administration,Intravenous administration may cause hypotension, cyanosis, and bronchospasm,Use in neonates: Intramuscular route is preferred; intravenous use may cause hyperbilirubinemia and kernicterus,Monitor coagulation parameters (INR) when used for warfarin reversal,Effect may be delayed; additional doses may be needed for full reversal
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to vitamin K1 or any component of the formulation
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
There are no significant food interactions with Vitamin K1 itself, but patients on warfarin should maintain consistent intake of Vitamin K1-rich foods (e.g., leafy greens, broccoli, Brussels sprouts) to keep INR stable.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Vitamin K1 is considered safe in pregnancy at recommended doses. No evidence of teratogenicity or fetotoxicity in first, second, or third trimesters. High doses (e.g., >5 mg/day) near term may theoretically increase risk of neonatal hyperbilirubinemia or hemolytic anemia, but risk is low.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Vitamin K1 is excreted into breast milk in small amounts; M/P ratio approximately 0.3. No adverse effects reported in nursing infants. Considered compatible with breastfeeding. Supplementation may be required for infants to prevent hemorrhagic disease of newborn if maternal intake low.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No dose adjustment required for standard obstetric use. Pharmacokinetics unchanged in pregnancy. For prevention of neonatal hemorrhage, standard dose of 1 mg IM at birth is used. In malabsorption or anticoagulant use, maternal supplementation may follow non-pregnant dosing (2.5-5 mg/day).
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Vitamin K1 (phytonadione) reverses warfarin-induced coagulopathy. For urgent reversal, IV administration is preferred but risk of anaphylaxis; use slow infusion. IM route avoided in anticoagulated patients due to hematoma risk. SC route less predictable. Neonatal prophylaxis prevents hemorrhagic disease of newborn. Monitor INR closely when initiating or discontinuing Vitamin K1 in patients on warfarin. High doses may cause warfarin resistance for up to 1 week.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take Vitamin K1 exactly as prescribed; do not change dose without consulting your doctor.,If you are on warfarin, maintain consistent dietary intake of Vitamin K1; sudden changes can affect INR.,Report any signs of bleeding or unusual bruising to your healthcare provider.,Avoid alcohol consumption as it may interfere with vitamin K metabolism.,Inform all healthcare providers that you are taking Vitamin K1, especially before surgery or dental procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs VITAMIN K1, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. VITAMIN K1 is a Vitamin K1 that works by Vitamin K1 (phytonadione) is a fat-soluble vitamin that serves as a cofactor for the enzyme gamma-glutamyl carboxylase, which catalyzes the carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) on vitamin K-dependent proteins, including clotting factors II, VII, IX, X, and proteins C and S. This carboxylation is essential for their calcium-binding activity and subsequent activation in the coagulation cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and VITAMIN K1 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of VITAMIN K1 is: 10 mg IV or IM as a single dose for anticoagulant reversal; may repeat every 12-24 hours as needed. For vitamin K deficiency: 2.5-10 mg PO, IM, or IV once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and VITAMIN K1 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. VITAMIN K1 is classified as Category C. Vitamin K1 is considered safe in pregnancy at recommended doses. No evidence of teratogenicity or fetotoxicity in first, second, or third trimesters. High doses (e.g., >5 mg/day) n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.